224 related articles for article (PubMed ID: 17205115)
1. The interplay between PolyQ and protein context delays aggregation by forming a reservoir of protofibrils.
Bulone D; Masino L; Thomas DJ; San Biagio PL; Pastore A
PLoS One; 2006 Dec; 1(1):e111. PubMed ID: 17205115
[TBL] [Abstract][Full Text] [Related]
2. Amyloid-like fibril formation by polyQ proteins: a critical balance between the polyQ length and the constraints imposed by the host protein.
Scarafone N; Pain C; Fratamico A; Gaspard G; Yilmaz N; Filée P; Galleni M; Matagne A; Dumoulin M
PLoS One; 2012; 7(3):e31253. PubMed ID: 22438863
[TBL] [Abstract][Full Text] [Related]
3. The length dependence of the polyQ-mediated protein aggregation.
Barton S; Jacak R; Khare SD; Ding F; Dokholyan NV
J Biol Chem; 2007 Aug; 282(35):25487-92. PubMed ID: 17591778
[TBL] [Abstract][Full Text] [Related]
4. Polyglutamine induced misfolding of huntingtin exon1 is modulated by the flanking sequences.
Lakhani VV; Ding F; Dokholyan NV
PLoS Comput Biol; 2010 Apr; 6(4):e1000772. PubMed ID: 20442863
[TBL] [Abstract][Full Text] [Related]
5. Solution structure of polyglutamine tracts in GST-polyglutamine fusion proteins.
Masino L; Kelly G; Leonard K; Trottier Y; Pastore A
FEBS Lett; 2002 Feb; 513(2-3):267-72. PubMed ID: 11904162
[TBL] [Abstract][Full Text] [Related]
6. Polyglutamine expansion mutation yields a pathological epitope linked to nucleation of protein aggregate: determinant of Huntington's disease onset.
Sugaya K; Matsubara S; Kagamihara Y; Kawata A; Hayashi H
PLoS One; 2007 Jul; 2(7):e635. PubMed ID: 17653262
[TBL] [Abstract][Full Text] [Related]
7. The rate of polyQ-mediated aggregation is dramatically affected by the number and location of surrounding domains.
Robertson AL; Bate MA; Buckle AM; Bottomley SP
J Mol Biol; 2011 Nov; 413(4):879-87. PubMed ID: 21945530
[TBL] [Abstract][Full Text] [Related]
8. Pathogenic and non-pathogenic polyglutamine tracts have similar structural properties: towards a length-dependent toxicity gradient.
Klein FA; Pastore A; Masino L; Zeder-Lutz G; Nierengarten H; Oulad-Abdelghani M; Altschuh D; Mandel JL; Trottier Y
J Mol Biol; 2007 Aug; 371(1):235-44. PubMed ID: 17560603
[TBL] [Abstract][Full Text] [Related]
9. Arginine is a disease modifier for polyQ disease models that stabilizes polyQ protein conformation.
Minakawa EN; Popiel HA; Tada M; Takahashi T; Yamane H; Saitoh Y; Takahashi Y; Ozawa D; Takeda A; Takeuchi T; Okamoto Y; Yamamoto K; Suzuki M; Fujita H; Ito C; Yagihara H; Saito Y; Watase K; Adachi H; Katsuno M; Mochizuki H; Shiraki K; Sobue G; Toda T; Wada K; Onodera O; Nagai Y
Brain; 2020 Jun; 143(6):1811-1825. PubMed ID: 32436573
[TBL] [Abstract][Full Text] [Related]
10. Exploding the Repeat Length Paradigm while Exploring Amyloid Toxicity in Huntington's Disease.
Wetzel R
Acc Chem Res; 2020 Oct; 53(10):2347-2357. PubMed ID: 32975927
[TBL] [Abstract][Full Text] [Related]
11. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.
Huang CC; Faber PW; Persichetti F; Mittal V; Vonsattel JP; MacDonald ME; Gusella JF
Somat Cell Mol Genet; 1998 Jul; 24(4):217-33. PubMed ID: 10410676
[TBL] [Abstract][Full Text] [Related]
12. Proteins Containing Expanded Polyglutamine Tracts and Neurodegenerative Disease.
Adegbuyiro A; Sedighi F; Pilkington AW; Groover S; Legleiter J
Biochemistry; 2017 Mar; 56(9):1199-1217. PubMed ID: 28170216
[TBL] [Abstract][Full Text] [Related]
13. Modeling the polyglutamine aggregation pathway in Huntington's disease: from basic studies to clinical applications.
Sugaya K
Subcell Biochem; 2012; 65():353-88. PubMed ID: 23225011
[TBL] [Abstract][Full Text] [Related]
14. Association of polyalanine and polyglutamine coiled coils mediates expansion disease-related protein aggregation and dysfunction.
Pelassa I; Corà D; Cesano F; Monje FJ; Montarolo PG; Fiumara F
Hum Mol Genet; 2014 Jul; 23(13):3402-20. PubMed ID: 24497578
[TBL] [Abstract][Full Text] [Related]
15. Multi-domain misfolding: understanding the aggregation pathway of polyglutamine proteins.
Saunders HM; Bottomley SP
Protein Eng Des Sel; 2009 Aug; 22(8):447-51. PubMed ID: 19589877
[TBL] [Abstract][Full Text] [Related]
16. Towards the treatment of polyglutamine diseases: the modulatory role of protein context.
Robertson AL; Bottomley SP
Curr Med Chem; 2010; 17(27):3058-68. PubMed ID: 20629626
[TBL] [Abstract][Full Text] [Related]
17. Polyglutamine expansion alters the dynamics and molecular architecture of aggregates in dentatorubropallidoluysian atrophy.
Hinz J; Lehnhardt L; Zakrzewski S; Zhang G; Ignatova Z
J Biol Chem; 2012 Jan; 287(3):2068-78. PubMed ID: 22134925
[TBL] [Abstract][Full Text] [Related]
18. Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine Diseases.
Minakawa EN; Nagai Y
Front Neurosci; 2021; 15():621996. PubMed ID: 33642983
[TBL] [Abstract][Full Text] [Related]
19. Neurotoxic protein oligomerisation associated with polyglutamine diseases.
Hands SL; Wyttenbach A
Acta Neuropathol; 2010 Oct; 120(4):419-37. PubMed ID: 20514488
[TBL] [Abstract][Full Text] [Related]
20. Fluorescence lifetime dynamics of enhanced green fluorescent protein in protein aggregates with expanded polyglutamine.
Ghukasyan V; Hsu CC; Liu CR; Kao FJ; Cheng TH
J Biomed Opt; 2010; 15(1):016008. PubMed ID: 20210454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
